Last reviewed · How we verify
ER OROS paliperidone and Olanzapine
This combination of an extended-release atypical antipsychotic (paliperidone) and another atypical antipsychotic (olanzapine) works by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.
This combination of an extended-release atypical antipsychotic (paliperidone) and another atypical antipsychotic (olanzapine) works by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances. Used for Schizophrenia, Bipolar disorder.
At a glance
| Generic name | ER OROS paliperidone and Olanzapine |
|---|---|
| Sponsor | Xian-Janssen Pharmaceutical Ltd. |
| Drug class | Atypical antipsychotic combination |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
Paliperidone is a dopamine D2 and serotonin 5-HT2A receptor antagonist formulated as an extended-release OROS (osmotic-controlled release oral delivery system) for sustained therapeutic levels. Olanzapine similarly antagonizes dopamine D2 and serotonin 5-HT2A receptors. The combination targets multiple neurotransmitter pathways implicated in schizophrenia and bipolar disorder to provide enhanced antipsychotic and mood-stabilizing effects.
Approved indications
- Schizophrenia
- Bipolar disorder
Common side effects
- Weight gain
- Metabolic syndrome
- Extrapyramidal symptoms
- Sedation
- Prolactin elevation
- Orthostatic hypotension
Key clinical trials
- A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia (PHASE3)
- A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia (PHASE3)
- A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia (PHASE3)
- A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: